Aadi Bioscience, Inc. (Aadi), is a privately held biopharmaceutical company focused on development and commercialization of nab-sirolimus (sirolimus albumin-bound nanoparticles for injectable suspension, ABI-009), in mTOR driven diseases. The company has initiated submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the treatment of advanced (metastatic or locally advanced) malignant PEComa (perivascular epithelioid-cell tumor) – a rare form of sarcoma driven by mTOR activation for which there is currently no approved therapy.

For information on our Expanded Access Program for nab-sirolimus (ABI-009) in patients with advanced PEComa and patients with malignancies with relevant genetic mutations or mTOR pathway activation please see: https://clinicaltrials.gov/ct2/show/NCT03817515

For information on our Pulmonary Arterial Hypertension study, please visit our study page:
http://pulmonaryhypertension001.com/